AmerisourceBergen Insights AmerisourceBergen

Listen as AmerisourceBergen experts discuss the continuing evolution of the biosimilar marketplace and share how we are inspiring confidence and uptake among key stakeholders.

The booming pipeline of cell and gene therapies, and their unique requirements, means both hope for patients and potential around eligibility and coverage barriers. We talk to experts from AmerisourceBergen and TrakCel about a new partnership for these innovative treatments that can improve speed to therapy, streamline the path to care, and create a heightened level of connectivity across the supply chain.

We're joined again by AmerisourceBergen's Peter Kounelis to discuss how the right PSAO should invest in and advocate for independent pharmacies. 

With independent pharmacy facing increasing pressures from the tight reimbursement landscape, how can the right contracting strategy help? Peter Kounelis, Vice President of Elevate Provider Network at AmerisourceBergen, joins us to discuss the evolution of the PSAO. Visit wearegnp.com to learn more about Elevate.

We’re discussing insulin biosimilars with Sean McGowan and Michelle Jesse from AmerisourceBergen’s biosimilars team, along with Brad Tallamy, Senior Director of Government Affairs at AmerisourceBergen. In part two of a two-part series on insulin biosimilars, we’ll talk about how pharmacies can prepare to dispense biosimilars once these products receive interchangeability status.

We’re revisiting the biosimilars market with Sean McGowan and Michelle Jesse from AmerisourceBergen’s biosimilars team, along with Brad Tallamy, Senior Director of Government Affairs at AmerisourceBergen. In part one of a two-part series on insulin biosimilars, we’ll talk about what these new drugs could mean for the category.